Futura Medical PLC's (LON:FUM) executive director and head of R&D Ken James speaks to Proactive London's Andrew Scott following the read-out from the phase III clinical trial of its erectile dysfunction gel.
James says while MED2005 showed strong efficacy, excellent safety and rapid speed of onset, the placebo had a “highly statistically significant” impact on the men in the control group of the experiment.
The placebo in this trial was DermaSys, developed by the company to deliver the active ingredient glyceryl trinitrate, or GTN for short.